Value | Category | Cases | |
---|---|---|---|
1 | Astrazeneca | 2 |
7.1%
|
2 | No sé | 16 |
57.1%
|
3 | Pfizer | 3 |
10.7%
|
4 | Sinopharm | 7 |
25%
|
Missing value | 380 |